Czech National Bank Acquires 3,172 Shares of Hologic, Inc. (NASDAQ:HOLX)

Czech National Bank increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 7.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 44,473 shares of the medical equipment provider’s stock after purchasing an additional 3,172 shares during the quarter. Czech National Bank’s holdings in Hologic were worth $3,302,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in HOLX. Massmutual Trust Co. FSB ADV lifted its holdings in Hologic by 24.7% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after buying an additional 137 shares in the last quarter. Graypoint LLC grew its stake in Hologic by 3.9% in the first quarter. Graypoint LLC now owns 3,871 shares of the medical equipment provider’s stock worth $302,000 after purchasing an additional 147 shares in the last quarter. Lincoln National Corp increased its holdings in Hologic by 4.0% during the 4th quarter. Lincoln National Corp now owns 4,675 shares of the medical equipment provider’s stock worth $334,000 after purchasing an additional 178 shares during the period. Allworth Financial LP raised its position in Hologic by 39.3% during the 4th quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 179 shares in the last quarter. Finally, Parallel Advisors LLC raised its holdings in shares of Hologic by 11.5% in the fourth quarter. Parallel Advisors LLC now owns 1,828 shares of the medical equipment provider’s stock valued at $131,000 after acquiring an additional 189 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insider Activity at Hologic

In other news, insider Brandon Schnittker sold 476 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the transaction, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the transaction, the chief executive officer now owns 1,157,562 shares in the company, valued at $92,755,443.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Brandon Schnittker sold 476 shares of the stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the sale, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,280 shares of company stock valued at $1,469,973. Corporate insiders own 1.75% of the company’s stock.

Hologic Stock Performance

Hologic stock traded down $1.58 during mid-day trading on Monday, hitting $82.06. The company had a trading volume of 529,835 shares, compared to its average volume of 1,641,894. The company has a current ratio of 3.99, a quick ratio of 3.29 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $19.15 billion, a price-to-earnings ratio of 42.67, a P/E/G ratio of 2.64 and a beta of 0.99. The company’s fifty day moving average is $76.29 and its 200-day moving average is $75.67. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the prior year, the firm posted $0.93 earnings per share. The company’s revenue was up 2.7% compared to the same quarter last year. Equities research analysts predict that Hologic, Inc. will post 4.08 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. JPMorgan Chase & Co. upped their target price on Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th. Stephens reaffirmed an “overweight” rating and set a $92.00 price objective on shares of Hologic in a research report on Tuesday, July 30th. Evercore ISI lifted their target price on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Tuesday, July 30th. Needham & Company LLC restated a “buy” rating and issued a $90.00 price target on shares of Hologic in a report on Tuesday, July 30th. Finally, StockNews.com lowered shares of Hologic from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $87.60.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.